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Background-—The relationship between plasma concentrations of betaine and choline metabolism and major cardiovascular
disease (CVD) end points remains unclear. We have evaluated the association between metabolites from the choline pathway and
risk of incident CVD and the potential modifying effect of Mediterranean diet interventions.
Methods and Results-—We designed a case-cohort study nested within the PREDIMED (Prevention With Mediterranean Diet) trial,
including 229 incident CVD cases and 751 randomly selected participants at baseline, followed up for 4.8 years. We used liquid
chromatography–tandem mass spectrometry to measure, at baseline and at 1 year of follow-up, plasma concentrations of 5
metabolites in the choline pathway: trimethylamine N-oxide, betaine, choline, phosphocholine, and a-glycerophosphocholine. We
have calculated a choline metabolite score using a weighted sum of these 5 metabolites. We used weighted Cox regression
models to estimate CVD risk. The multivariable hazard ratios (95% conﬁdence intervals) per 1-SD increase in choline and a-
glycerophosphocholine metabolites were 1.24 (1.05–1.46) and 1.24 (1.03–1.50), respectively. The baseline betaine/choline ratio
was inversely associated with CVD. The baseline choline metabolite score was associated with a 2.21-fold higher risk of CVD
across extreme quartiles (95% conﬁdence interval, 1.36–3.59; P<0.001 for trend) and a 2.27-fold higher risk of stroke (95%
conﬁdence interval, 1.24–4.16; P<0.001 for trend). Participants in the higher quartiles of the score who were randomly assigned
to the control group had a higher risk of CVD compared with participants in the lower quartile and assigned to the Mediterranean
diet groups (P=0.05 for interaction). No signiﬁcant associations were observed for 1-year changes in individual plasma metabolites
and CVD.
Conclusions-—A metabolite score combining plasma metabolites from the choline pathway was associated with an increased risk
of CVD in a Mediterranean population at high cardiovascular risk.
Clinical Trial Registration-—URL: http://www.controlled-trials.com. Unique identiﬁer: ISRCTN35739639. ( J Am Heart Assoc.
2017;6:e006524. DOI: 10.1161/JAHA.117.006524.)
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ORIGINAL RESEARCH
I n the past few years, interest has emerged on the role ofplasma metabolites in the development of cardiometabolic
diseases and on how diet can inﬂuence disease risk through
inducing changes in the metabolome proﬁle. Lately, metabo-
lites from the choline pathway have received increasing
attention for its link with the gut microbiota and the potential
mechanistic relevance of them.1 In particular, these studies
have focused on metabolites associated with betaine and
choline metabolism and the gut microbiota–dependent
metabolite, trimethylamine N-oxide (TMAO), which have been
associated with atherosclerosis development and cardiovas-
cular disease (CVD).1,2 Choline can be oxidized to betaine in
humans, and the betaine/choline ratio has been inversely
associated with nonalcoholic fatty liver disease,3 but its
association with CVD has not been previously described.
Dietary lipid phosphatidylcholine is the primary source of
choline, and catabolism of betaine and choline by intestinal
microbes leads to TMAO production.4 Foods, such as meat,
egg yolks, and high-fat dairy products, which are rich in
phosphatidylcholine, choline, carnitine, and TMA, serve as
dietary precursors for TMAO generation in mice and humans.2
Dietary supplementation with these metabolites in mice
promoted atherosclerosis, and suppression of the microbiota
with antibiotics prevented the effect of dietary choline in
enhancing atherosclerosis.4 This evidence suggests that diet
could modulate intestinal microbiota composition and, sub-
sequently, the ability to synthesize trimethylamine and TMAO,
thus providing a mechanistic link between diet, gut
microbiome, and atherosclerosis.1,2,5,6 However, not all
human studies have conﬁrmed the association between
TMAO and cardiovascular events.7–10 Indeed, the relation
between plasma concentration of choline pathway metabo-
lites and the incidence of hard CVD end points in a
population-based level and the role that diet may play in
these associations remain to be elucidated.
We hypothesized that higher concentrations at baseline
and 1-year changes in choline pathway metabolites (TMAO,
betaine, choline, phosphocholine, and a-glycerophosphocho-
line) would be associated with the risk of cardiovascular
events. The Mediterranean diet (MedDiet), which is high in
plant-based foods, has been linked with a reduced risk of
cardiovascular risk factors and CVD.11 Because previous
evidence suggests that excessive consumption of phos-
phatidylcholine and choline could be reduced by consuming
a plant-based or high-ﬁber diet,4 such as the MedDiet, we
hypothesized that the associations between choline metabo-
lites and CVD will be modiﬁed by MedDiet interventions.
Using a case-cohort study conducted in participants at high
cardiovascular risk from the PREDIMED (Prevention With
Mediterranean Diet) Study, we aimed to address the following:
(1) whether baseline choline pathway metabolites (and their
1-year changes) predict future risk of CVD and (2) whether
these associations are mitigated by a MedDiet intervention.
Methods
Study Population
We designed a case-cohort study in the framework of the
PREDIMED Study. The design and protocol of the PREDIMED
Study (http://www.predimed.es) have been described in
detail elsewhere.11,12 Brieﬂy, the PREDIMED Study was a
large, multicenter, parallel-group, randomized, controlled trial
aimed at evaluating the effect of the MedDiet on the primary
prevention of CVD. A total of 7447 participants, aged 55 to
80 years and at high cardiovascular risk but free of CVD at
baseline, were randomly assigned to receive 1 of the following
3 interventions: MedDiet supplemented with extravirgin olive
oil, MedDiet supplemented with mixed nuts, or an equivalent
education program with advice to reduce the intake of all
types of fat (control group). The primary end point of the
PREDIMED trial was a composite of cardiovascular events
(myocardial infarction, stroke, or death from cardiovascular
causes); 288 incident CVD cases occurred during 4.8 years of
follow-up.
In a case-cohort study design, all incident cases and a
randomly selected sample of the original cohort were selected
as participants. In the present study, we included all the
incident cases of CVD diagnosed during the follow-up and a
random sample of 10% of the original PREDIMED trial
Clinical Perspective
What Is New?
• Baseline plasma concentrations of choline pathway metabo-
lites (choline, phosphocholine, and a-glycerophosphocho-
line) and a metabolite score combining choline pathway
metabolites were associated with the risk of major cardio-
vascular events after 4.8 years of follow-up in a Mediter-
ranean population at high cardiovascular risk.
What Are the Clinical Implications?
• Our ﬁndings suggest that metabolites from choline path-
ways may play a role in the development of cardiovascular
disease.
• The present work may have important public health
implications for focusing on dietary interventions, such as
adhering to a Mediterranean diet and reducing the intake of
animal products, to improve metabolite proﬁles and,
consequently, the risk of cardiovascular disease.
• However, further research is needed to replicate these
results in other populations and investigate the potential
mechanisms underlying the associations between metabo-
lite proﬁles and cardiovascular disease.
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(referred to as the “subcohort,” which by its random selection
may include some cases) with available EDTA plasma samples
at baseline. With this design, we maintained the original
randomization scheme of the trial. The present analysis
included a total of 980 participants, 751 were noncases and
229 were cases (there were 37 overlapping cases between
the subcohort and the total cases). Of these participants, 923
of the 980 had available samples after 1 year of follow-up and
were included in the 1-year change analyses (Figure S1). We
deﬁned cases as the participants who developed a major
cardiovascular event (stroke, myocardial infarction, or cardio-
vascular death) during follow-up. We deﬁned subcohort as the
random sample selected from the full roster of the PREDIMED
Study (including 37 incident CVD cases, which were deﬁned
as internal cases). The 37 overlapping cases were treated as
cases in the analysis (total CVD cases, 229). We deﬁned
external cases as the cases that were not randomly included
in the subcohort. All participants provided written informed
consent, according to a protocol approved by the institutional
review boards before inclusion in the study.
Metabolite Proﬁling
At baseline and at yearly follow-up visits, trained nurses
collected fasting blood samples from the PREDIMED partic-
ipants. After an overnight fast, tubes for EDTA plasma were
collected and aliquots were coded and kept refrigerated until
they were stored at 80°C in freezers. Pairs of samples
(baseline and ﬁrst-year visit) were randomly ordered and
shipped on dry ice to the Broad Institute (Cambridge, MA) for
the metabolomics analysis.
The present work was a hypothesis-driven analysis of 5
metabolites from the choline pathway. Polar plasma metabo-
lites, including TMAO, choline, betaine, phosphocholine, and
a-glycerophosphocholine, were proﬁled using liquid chro-
matography–tandem mass spectrometry on a system
composed of a Shimadzu Nexera X2 U-HPLC coupled to a Q
Exactive hybrid quadrupole orbitrap mass spectrometer.13
Metabolite extracts were prepared from plasma samples
(10 lL) via protein precipitation with the addition of 9 volumes
of 74.9:24.9:0.2 v/v/v acetonitrile/methanol/formic acid
containing stable isotope-labelled internal standards (valine-
d8 and phenylalanine-d8). The samples were centrifuged
(10 minutes, 9000g, 4°C), and the supernatants were injected
directly onto a 15092-mm, 3-lm Atlantis HILIC column. The
column was eluted isocratically at a ﬂow rate of 250 lL/min
with 5% mobile phase A (10 mmol/L ammonium formate and
0.1% formic acid in water) for 0.5 minutes, followed by a linear
gradient to 40% mobile phase B (acetonitrile with 0.1% formic
acid) over 10 minutes. Mass spectrometry analyses were
performed using electrospray ionization in the positive ion mode
using full-scan analysis over 70 to 800 m/z at 70 000
resolutions and a 3-Hz data acquisition rate. Other mass
spectrometry settings were as follows: sheath gas, 40; sweep
gas, 2; spray voltage, 3.5 kV; capillary temperature, 350°C; S-
lens, RF40; heater temperature, 300°C;microscans, 1; automatic
gain control target, 1e6; and maximum ion time, 250 millisec-
onds. Metabolite identities were conﬁrmed using authentic
reference standards. Raw datawere processed using TraceFinder
software and Progenesis QI. Internal standard peak areas were
monitored for quality control and to ensure system performance
throughout analyses. Pooled plasma reference sampleswere also
inserted every 20 samples as an additional quality control.
Ascertainment of CVD Cases
For the present analysis, the primary end point was a composite
of cardiovascular events (myocardial infarction, stroke, or
death from cardiovascular causes). As a secondary end point,
we separately analyzed incident stroke, because this was the
most common element included in the deﬁnition of the
composite primary end point in the PREDIMED Study. Infor-
mation onmajor cardiovascular events was updated on a yearly
basis and obtained from the continuous contact with partici-
pants and their families during the trial, contact with general
practitioners, the yearly comprehensive review of medical
records, and consultation of the National Death Index. The end
point was determined by review of the Endpoint Adjudication
Committee that was blinded to the intervention group. Only
conﬁrmed cases were included in the analyses.
Covariate Assessment
At baseline and at yearly follow-up visits, a questionnaire
about lifestyle variables, educational achievement, history of
diseases, medication use, and family history of disease was
administered. Physical activity was assessed using the
validated Spanish version of the Minnesota Leisure-Time
Physical Activity questionnaire.14 Participants were consid-
ered to have diabetes mellitus, hypercholesterolemia, or
hypertension if they had previously been diagnosed and/or
they were being treated with antidiabetic, cholesterol-low-
ering, or antihypertensive agents, respectively. Trained dieti-
tians completed a 137-item validated semiquantitative food
frequency questionnaire in face-to-face interviews with par-
ticipants.15 We used Spanish food composition tables to
estimate energy and nutrient intake.16 Trained personnel took
anthropometric and blood pressure measurements.
Statistical Analysis
We applied a rank-based inverse normal transformation to
approximate a normal distribution of metabolite levels.17
Baseline characteristics are presented per case status and for
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quartiles of the choline score as the mean (SD) for quanti-
tative traits and number (percentage) for categorical variables.
Baseline characteristics were compared between cases and
noncases using t tests for continuous variables and v2 tests
for categorical variables.
We used Cox proportional hazard models, with Barlow
weights (to account for oversampling of cases in the study
design18), to estimate hazard ratios (HRs) and their 95%
conﬁdence intervals (CIs) for the primary combined end point
of CVD and, separately, for nonfatal stroke. In all Cox models,
Barlow weights were used to account for oversampling of
cases in the study design. Noncases in the subcohort were
weighted inversely proportional to the sampling fraction (ie, in
our study, the weight was 10). For noncases, observation time
began on the date of their randomization and ended on their
date of death (from noncardiovascular causes), the study end
date (December 1, 2010), or the date of the last medical visit
(if they had stopped attending scheduled intervention
appointments), whichever came ﬁrst. Cases had a weight of
1 at the instant the individual experienced an end point, and
observation time was the time when the participant developed
CVD. Incident internal cases were treated as noncases
(observation time began on the date that they were random-
ized and ended the instant the individual died) until they
became cases, and at such instant their weight changed.
Cox models were adjusted for age (years), sex (men/
women), family history of premature heart disease (yes/no),
smoking (never, former, or current), and body mass index (kg/
m2), and were stratiﬁed by intervention group (both MedDiet
interventions and low-fat control group) (model 1). Model 2
was additionally adjusted for physical activity (metabolic
equivalent tasks in min/d), baseline hypertension (yes/no),
dyslipidemia (yes/no), and diabetes mellitus (yes/no). Base-
line individual plasma metabolites were analyzed as both
continuous variables (1-SD increment in transformed concen-
tration of metabolites) and using quartiles (using cut points
deﬁned among noncases). To test for the linear trend across
quartiles, the median of each quartile was assigned and
analyzed as a continuous variable. To account for multiple
testing, we adjusted P values of the multivariable-adjusted
associations between 1-SD increment in metabolite concen-
tration and CVD risk using the Benjamin-Hochberg procedure.
In addition, we calculated a choline metabolite score as the
weighted sum of concentrations of 5 metabolites from the
choline pathway and modeled the score as a main exposure
variable in the Cox model. The weight for each metabolite was
the regression coefﬁcient for a 1-SD increment in the plasma
concentration estimated from the multivariable Cox regression
model. We also calculated the ratio between betaine and choline
(by dividing the raw values and then applying inverse normal
transformations). We conducted stratiﬁed analyses by sex, age
(<65 versus ≥65 years), obesity (<30 versus ≥30 kg/m2),
smoking status (current/former versus never), family history of
premature coronary heart disease, baseline type 2 diabetes
mellitus, baseline hypertension, and baseline dyslipidemia. The
interactions between these variables of stratiﬁcation and the
choline score were tested by adding multiplicative terms into
themultivariable Coxmodels; a likelihood ratio test was used for
testing statistical signiﬁcance of the interaction term.
We also examined the associations of 1-year changes in
the individual plasma metabolites with CVD. We used the
same Cox regression models as in the baseline analyses, but
we further adjusted for baseline levels and an interaction term
between these metabolites at baseline and 1-year change
(both as continuous variables). We repeated the analysis using
incident stroke as the outcome, both including and excluding
the nonstroke CVD cases (ie, treating the 113 nonstroke CVD
cases as noncases or removing them from analyses), and
found similar results. Therefore, we present stroke results
only after removing the nonstroke CVD cases.
To examine the combined associations of the MedDiet
interventions and choline pathway metabolites with the
incidence of CVD, we categorized the participants into joint
subgroups, according to the assignment to the intervention
group (MedDiet merged versus control group), quartiles of the
choline metabolite score, and betaine/choline ratio. We used
participants assigned to the control group and the ﬁrst
quartile of the choline score as the reference group; we also
used participants in the MedDiet group and the ﬁrst quartile
of the betaine/choline ratio as the reference group. We
estimated HRs and their 95% CIs for CVD, according to this
joint categorization, using the same models as in the previous
analysis. To test the interaction between the MedDiet and the
metabolite score and betaine/choline ratio, we added a
multiplicative term (1 df) between intervention group (Med-
Diet merged versus control group) and the continuous score
into the multivariable Cox models. In secondary analysis, we
further adjusted multivariable model 2 for previous metabo-
lites that predicted CVD in our population, including a
weighted score of branched-chain amino acids (isoleucine,
leucine, and valine)19; short-chain (C2carnitine to C7car-
nitine), medium-chain (C8carnitine to C14:2carnitine), and
long-chain (C16carnitine to C26carnitine) acylcarnitines
score20; and glutamine/glutamate ratio.21 In addition, we
further adjusted the models for medication use (dyslipidemia,
antihypertensive, and antidiabetic medications).
All statistical analyses were performed using SAS version
9.4 and R version 2.13.0. P<0.05 was considered statistically
signiﬁcant.
Results
The baseline characteristics of the 980 participants are shown
in Table 1, according to whether they had a major CVD event
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during the 4.8 years of follow-up and quartiles of the choline
metabolite score. Participants in the higher quartile of the
score had higher risk proﬁles at baseline than those in the
lower quartile of the score, including older age and higher
prevalence of hypertension, dyslipidemia, and diabetes mel-
litus; they were also more likely to smoke. The characteristics
of the metabolites included in the analysis and the pathways
in which they are involved are described in Table S1. A
diagram of the choline pathway is presented in Figure S2. A
heat map of Spearman correlation coefﬁcients of the plasma
metabolites analyzed in the present study is shown in
Figure S3. Means and SD of plasma metabolite concentra-
tions are presented in Table S2 for the total population and in
Table S3 stratiﬁed by the intervention group.
Plasma Concentrations of Choline Pathway
Metabolites and CVD
The associations between individual plasma metabolites and
the choline metabolite score with the risk of CVD and stroke
are presented in Table 2. Compared with participants in the
lowest quartile of choline, those in the highest quartile had a
signiﬁcantly higher risk of CVD after adjusting for cardiovas-
cular risk factors (HR [95% CI], 1.72 [1.05–2.81]; P=0.01 for
trend). A 1-SD increment in baseline concentrations of choline
and a-glycerophosphocholine was associated with higher risk
of CVD incidence. Similar, but weakened, associations were
observed when stroke was used as the end point (Table 2). In
the multivariable adjusted models, the choline score was
associated with a 2.21-fold higher risk of CVD and a 2.27-fold
higher risk of stroke across quartiles (HR [95% CI], 2.21
[1.36–3.59] [P<0.001 for trend] and 2.27 [1.24–4.16]
[P<0.001 for trend], respectively). The betaine/choline ratio
was inversely associated with the incidence of CVD (HR [95%
CI], 0.57 [0.35–0.92]; P=0.04 for trend) but not with the
incidence of stroke alone. The HRs associated with a 1-SD
increment in the choline metabolite score and the betaine/
choline ratio were 2.27 (95% CI, 1.36–3.80) and 0.80 (95% CI,
0.68–0.94), respectively. Subgroup analysis for the associa-
tion between the choline score and the risk of CVD is shown
in Table 3. We observed similar associations between the
score and CVD after adjusting for baseline plasma
Table 1. Baseline Characteristics of the Study Population
Characteristics Cases (n=229) Noncases (n=751)
Quartiles of Choline Metabolite Score*
1 (n=231) 2 (n=256) 3 (n=246) 4 (n=247)
Age, meanSD, y 69.46.5 67.06 66.35.5 67.76.5 68.05.9 68.36.2
Female sex, n (%) 91 (39.7) 437 (58.1) 151 (67.1) 135 (53.3) 118 (48.1) 137 (46.6)
Body mass index, meanSD, kg/m2 29.63.7 29.73.6 29.93.7 29.53.7 29.73.6 29.73.6
Intervention group, n (%)
MedDiet+EVOO 82 (35.8) 281 (37.4) 74 (32.9) 94 (37.1) 86 (35.1) 121 (41.1)
MedDiet+nuts 65 (28.4) 249 (33.1) 72 (32.0) 74 (29.2) 82 (33.4) 98 (33.3)
Control 82 (35.8) 221 (29.4) 79 (35.1) 85 (33.6) 77 (31.4) 75 (27.5)
Family history of CHD, n (%) 44 (19.2) 193 (25.7) 66 (29.3) 60 (23.7) 53 (21.6) 63 (21.4)
Hypertension, n (%) 189 (82.5) 628 (83.7) 183 (81.3) 215 (84.9) 203 (82.8) 246 (83.6)
Dyslipidemia, n (%) 134 (58.5) 558 (74.3) 146 (64.9) 179 (70.7) 176 (71.8) 212 (72.1)
Diabetes mellitus, n (%) 147 (64.2) 347 (46.2) 115 (51.1) 129 (50.9) 121 (49.4) 154 (52.4)
Antihypertensive medication, n (%) 167 (72.9) 564 (75.1) 173 (76.9) 193 (76.3) 173 (70.6) 217 (73.8)
Lipid-lowering medication, n (%) 91 (39.7) 367 (48.8) 94 (41.8) 119 (47.0) 118 (48.2) 143 (48.6)
Oral antidiabetic agents, n (%) 109 (47.60) 225 (29.96) 65 (28.9) 88 (34.8) 88 (35.9) 114 (38.8)
Smoking, n (%)
Never 104 (45.4) 474 (63.1) 153 (68.0) 146 (57.7) 135 (55.1) 161 (54.7)
Former 79 (34.5) 184 (24.5) 42 (18.6) 68 (26.8) 80 (32.6) 89 (30.2)
Current 46 (20.1) 93 (12.4) 30 (13.3) 39 (12.4) 30 (12.2) 44 (14.9)
Cases have a composite of cardiovascular disease events (myocardial infarction, stroke, and cardiovascular death). CHD indicates coronary heart disease; EVOO, extravirgin olive oil; and
MedDiet, Mediterranean diet.
*Quartiles were calculated on the basis of the distribution of the choline metabolite score in the subcohort. Inverse normal transformation was applied to raw values of metabolites. To
build the score, we applied a weighted sum of concentrations of 5 metabolites in the choline pathway (trimethylamine N-oxide, betaine, choline, phosphocholine, and
a-glycerophosphocholine).
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Table 2. Risk of CVD and Stroke by Baseline Plasma Concentrations of Choline Metabolites in the PREDIMED Study
Variable
HR (95% CI) for Quartiles of Plasma Metabolite Concentration
PTrend Value
HR (95% CI) per
1-SD Increment1 2 3 4
CVD
TMAO
No. of cases 43 69 58 59 . . . . . .
Multivariable model 1 Ref. 1.44 (0.90–2.28) 1.13 (0.70–1.80) 1.25 (0.78–1.99) 0.60 1.04 (0.89–1.21)
Multivariable model 2 Ref. 1.37 (0.85–2.22) 1.08 (0.66–1.76) 1.09 (0.67–1.77) 0.94 1.01 (0.85–1.18)
Betaine
No. of cases 51 57 60 61 . . . . . .
Multivariable model 1 Ref. 0.94 (0.59–1.48) 1.03 (0.66–1.61) 0.77 (0.49–1.21) 0.30 0.89 (0.77–1.03)
Multivariable model 2 Ref. 1.00 (0.63–1.60) 1.23 (0.77–1.97) 0.91 (0.77–1.49) 0.87 0.95 (0.82–1.12)
Choline
No. of cases 34 43 68 84 . . . . . .
Multivariable model 1 Ref. 1.03 (0.62–1.71) 1.30 (0.78–2.14) 1.55 (0.96–2.52) 0.03 1.21 (1.02–1.43)
Multivariable model 2 Ref. 1.08 (0.64–1.81) 1.48 (0.89–2.46) 1.72 (1.05–2.81) 0.01 1.24 (1.05–1.46)
Phosphocholine
No. of cases 46 58 57 68 . . . . . .
Multivariable model 1 Ref. 1.16 (0.73–1.85) 1.29 (0.81–2.05) 1.40 (0.89–2.24) 0.12 1.09 (0.92–1.28)
Multivariable model 2 Ref. 1.18 (0.73–1.93) 1.27 (0.77–2.08) 1.41 (0.87–2.28) 0.15 1.09 (0.92–1.30)
a-Glycerophosphocholine
No. of cases 51 56 47 75 . . . . . .
Multivariable model 1 Ref. 0.89 (0.56–1.42) 0.79 (0.50–1.26) 1.26 (0.81–1.97) 0.30 1.20 (1.00–1.44)
Multivariable model 2 Ref. 0.99 (0.62–1.57) 0.92 (0.57–1.51) 1.42 (0.89–2.28) 0.14 1.24 (1.03–1.50)
Choline metabolite score
No. of cases 39 64 57 106 . . . . . .
Multivariable model 1 Ref. 1.26 (0.77–2.05) 1.09 (0.64–1.81) 1.91 (1.20–3.04) <0.001 2.07 (1.25–3.41)
Multivariable model 2 Ref. 1.33 (0.81–2.19) 1.25 (0.74–2.11) 2.21 (1.36–3.59) <0.001 2.27 (1.36–3.80)
Betaine/choline ratio
No. of cases 74 52 63 40 . . . . . .
Multivariable model 1 Ref. 0.70 (0.46–1.08) 0.86 (0.56–1.30) 0.50 (0.32–0.78) <0.001 0.77 (0.66–0.90)
Multivariable model 2 Ref. 0.73 (0.47–1.14) 0.86 (0.55–1.34) 0.57 (0.35–0.92) 0.04 0.80 (0.68–0.94)
Stroke
TMAO
No. of cases 24 38 31 25 . . . . . .
Multivariable model 1 Ref. 1.32 (0.74–2.35) 1.06 (0.58–1.94) 0.91 (0.49–1.69) 0.55 0.93 (0.77–1.12)
Multivariable model 2 Ref. 1.19 (0.65–2.17) 0.98 (0.53–1.84) 0.78 (0.41–1.49) 0.31 0.89 (0.73–1.10)
Betaine
No. of cases 27 32 32 27 . . . . . .
Multivariable model 1 Ref. 1.08 (0.61–1.91) 1.06 (0.60–1.86) 0.73 (0.39–1.34) 0.29 0.91 (0.75–1.11)
Multivariable model 2 Ref. 1.15 (0.64–2.04) 1.32 (0.74–2.36) 0.89 (0.46–1.71) 0.85 1.00 (0.81–1.23)
Choline
No. of cases 19 24 31 44 . . . . . .
Multivariable model 1 Ref. 1.04 (0.54–2.00) 1.18 (0.59–2.33) 1.58 (0.84–2.99) 0.10 1.24 (0.98–1.56)
Multivariable model 2 Ref. 1.08 (0.56–2.09) 1.33 (0.67–2.62) 1.73 (0.91–3.29) 0.06 1.27 (1.02–1.59)
Continued
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concentrations of branched chain amino acids, acylcarnitines,
and glutamine/glutamate ratio: the HR per SD was 2.27 (95%
CI, 1.27–4.08). Similarly, the HR per SD for betaine/choline
ratio after adjustment for these metabolites was 0.77 (95% CI,
0.64–0.92). The associations between 1-SD increment in
choline and a-glycerophosphocholine remained signiﬁcant
after multiple-comparison adjustment. The adjusted P values
were 0.03 and 0.04, respectively. Further adjusting the
models for medication use (dyslipidemia, antihypertensive,
and antidiabetic medications) did not change the results. For
the overall score, the HR per SD was 2.36 (95% CI, 1.39–
4.02); and for the betaine/choline ratio, the HR per SD was
0.82 (95% CI, 0.69–0.96).
Choline Pathway Metabolites and MedDiet
Interventions
As illustrated in the Figure, we observed a higher risk of CVD
events for those participants who had a higher choline score
(quartiles 2–4) and were assigned to the control group
compared with those with lower levels in the score and
assigned to the MedDiet intervention groups (HR, 2.37; 95%
CI, 1.34–4.18). Participants with a higher betaine/choline
ratio and assigned to the MedDiet intervention group had a
lower risk of CVD compared with those with a lower ratio and
in the control group (HR, 0.36; 95% CI, 0.21–0.63) (Figure).
The P values for interaction between the continuous choline
score, the betaine/choline ratio, and the intervention group
(MedDiet versus control group) and CVD were nonsigniﬁcant
at P=0.05 and P=0.93, respectively (Figure). Likewise, partic-
ipants with a higher score and in the control group also had a
higher risk of stroke (HR, 2.66; 95% CI, 1.22–5.80) (Table S4).
One-Year Changes in Plasma Concentrations of
Metabolites and CVD
No signiﬁcant associations were observed for quartiles of
1-year changes in plasma concentrations of individual
metabolites and the risk of CVD and stroke. In multivariable
model 1, a 1-SD increment of betaine after 1 yearwas associated
with lower risk of CVD (HR [95% CI], 0.80 [0.66–0.98]), but the
association was attenuated in multivariable model 2 and when
analyzed as quartiles of the change (Table S5).
Discussion
In this case-cohort study nested within the PREDIMED Study,
we observed that baseline plasma concentrations of choline
pathway metabolites (choline, phosphocholine, and
Table 2. Continued
Variable
HR (95% CI) for Quartiles of Plasma Metabolite Concentration
PTrend Value
HR (95% CI) per
1-SD Increment1 2 3 4
Phosphocholine
No. of cases 23 26 29 40 . . . . . .
Multivariable model 1 Ref. 0.95 (0.51–1.79) 1.33 (0.72–2.44) 1.67 (0.94–2.98) 0.04 1.23 (0.99–1.53)
Multivariable model 2 Ref. 0.96 (0.50–1.84) 1.28 (0.66–2.46) 1.70 (0.93–3.11) 0.05 1.25 (1.00–1.57)
a-Glycerophosphocholine
No. of cases 31 23 23 41 . . . . . .
Multivariable model 1 Ref. 0.63 (0.34–1.18) 0.63 (0.35–1.15) 1.15 (0.67–1.98) 0.52 1.17 (0.91–1.50)
Multivariable model 2 Ref. 0.68 (0.36–1.26) 0.71 (0.38–1.35) 1.29 (0.74–2.25) 0.31 1.22 (0.96–1.55)
Choline metabolite score
No. of cases 21 25 22 50 . . . . . .
Multivariable model 1 Ref. 1.10 (0.58–2.09) 0.78 (0.40–1.53) 1.94 (1.07–3.50) 0.03 1.83 (1.13–2.97)
Multivariable model 2 Ref. 1.21 (0.63–2.33) 0.88 (0.44–1.76) 2.27 (1.24–4.16) 0.01 2.07 (1.25–3.44)
Betaine/choline ratio
No. of cases 38 26 33 21 . . . . . .
Multivariable model 1 Ref. 0.68 (0.39–1.20) 0.88 (0.52–1.52) 0.54 (0.30–0.97) 0.08 0.78 (0.64–0.95)
Multivariable model 2 Ref. 0.73 (0.41–1.30) 0.91 (0.52–1.61) 0.66 (0.35–1.26) 0.31 0.83 (0.66–1.03)
Inverse normal transformation was applied to raw values of metabolites. To build the score, we applied a weighted sum of concentrations of 5 metabolites in the choline pathway (TMAO,
betaine, choline, phosphocholine, and a-glycerophosphocholine). The betaine/choline ratio was calculated by dividing the raw values and then applying inverse normal transformations.
Model 1 was adjusted for age, sex, body mass index, family history of premature heart disease, and smoking and was stratiﬁed by intervention group (only in the overall analyses). Model 2
was adjusted as for model 1 and for physical activity (metabolic equivalent task units in min/d), hypertension, dyslipidemia, and diabetes mellitus. CI indicates conﬁdence interval; CVD,
cardiovascular disease; HR, hazard ratio; PREDIMED, Prevention With Mediterranean Diet; Ref., reference; and TMAO, trimethylamine N-oxide.
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a-glycerophosphocholine) and a metabolite score combining
choline pathway metabolites were associated with the risk of
major cardiovascular events after 4.8 years of follow-up.
Higher concentrations of a choline metabolite score were
associated with higher risk of CVD and stroke, whereas the
ratio of betaine/choline was inversely associated with CVD
but not with stroke alone. Therefore, our ﬁndings suggest that
metabolites from choline pathways may play a role in the
development of CVD.
Plasma metabolites in the choline pathway, which are
derivatives from dietary sources and may also reﬂect
alterations in the gut microbiota, have been previously related
to multifactorial diseases, such as obesity, type 2 diabetes
mellitus, and CVD.1,22 Several mechanisms are probably
involved, including modulation of host energy metabolism, gut
epithelial permeability, gut peptide hormone secretion, and an
increase in metabolic endotoxemia and inﬂammatory sta-
tus.23–25 One of the mechanisms explaining the potential
associations between some of these metabolites and CVD is
the potential proatherogenic effects.6 It has been shown that
TMAO can inhibit reverse cholesterol transport, alter sterol
metabolism,26 and affect platelet activation and thrombosis
risk.27 However, the associations between plasma metabo-
lites within the choline pathway, identiﬁed using novel high-
throughput metabolomics techniques, and the incidence of
CVD at a population-based level have only recently been
reported.
To our knowledge, this is the ﬁrst case-cohort study in a
clinical trial setting showing that higher concentrations of
plasma choline and a-glycerophosphocholine are associated
with an increased risk of CVD; higher concentrations of
choline and phosphocholine are associated with a higher risk
of stroke. The associations between dietary and plasma
choline and other metabolites from this pathway and CVD
events in humans are still unclear. Epidemiologic studies have
reported inconsistent associations between systemic levels of
choline and betaine and cardiovascular events.6,7,28,29
Recently, it has been reported that higher plasma choline
and betaine levels were associated with 1.9- and 1.4-fold
increased risks, respectively, of major adverse cardiac events
after 3 years of follow-up in patients undergoing elective
diagnostic coronary angiography.29 However, these associa-
tions were attenuated and no longer signiﬁcant when TMAO
was included in the models.29 In contrast, betaine supple-
mentation attenuated atherosclerotic lesions in apolipopro-
tein E/ mice.30 In our study, the betaine/choline ratio was
inversely associated with CVD in individuals at high cardio-
vascular risk, suggesting that the balance between systemic
concentrations of betaine and choline could be of importance
for the prevention of cardiovascular events. However, we
found no signiﬁcant associations between 1-year changes in
choline pathway metabolites and the incidence of CVD. It is
possible that 1 year was a short period to observe these
associations, or other mechanisms and pathways are impli-
cated in the pathogenesis of CVD in our population.
Interestingly, in a cross-sectional subset of the Nutrition,
Aging and Memory in Elders cohort,31 higher plasma choline
concentrations were associated with an unfavorable car-
diometabolic risk factor proﬁle (lower high-density lipoprotein
cholesterol and higher body mass index). They were also
associated with greater odds of large-vessel cerebral vascular
disease and history of CVD but lower odds of small-vessel
cerebral vascular disease. On the contrary, plasma betaine
Table 3. Subgroup Analysis for the Associations Between
Choline Metabolite Score and Risk of CVD
Characteristics
HR (95% CI) Per SD
Increment
P Value for
Interaction
Sex
Men (n=452) 2.31 (1.13–4.71) 0.83
Women (n=528) 2.23 (1.03–4.83)
Age, y
≤65 (n=338) 2.67 (1.06–6.69) 0.49
>65 (n=598) 2.42 (1.27–4.64)
Obesity, kg/m2
≤30 (n=535) 2.65 (1.31–5.35) 0.79
>30 (n=445) 2.04 (0.92–4.52)
Smoking status
Current/former smoking
(n=402)
2.45 (1.19–5.06) 0.63
Ever smoking (n=578) 2.40 (1.09–5.28)
Family history of CHD
Yes (n=237) 2.19 (1.22–3.95) 0.15
No (n=743) 3.78 (0.84–5.42)
Baseline type 2 diabetes mellitus
Yes (n=486) 2.22 (1.00–4.92) 0.87
No (n=494) 2.37 (1.20–4.69)
Baseline hypertension
Yes (n=817) 1.94 (1.08–3.46) 0.36
No (n=163) 3.12 (0.75–5.65)
Baseline dyslipidemia
Yes (n=692) 2.55 (1.31–4.94) 0.73
No (n=288) 2.03 (0.86–4.78)
Multivariate adjusted HRs (95% CIs) of incident CVD for 1-SD increment in the baseline
choline metabolite score. Data were adjusted for age, sex, body mass index, physical
activity (metabolic equivalent task units in min/d), family history of premature heart
disease, smoking, hypertension, dyslipidemia, and diabetes mellitus and stratiﬁed by
intervention group, except for the stratiﬁcation variable in each model. P values for
interaction were derived from Cox models adjusted as above, including an interaction
term between the stratiﬁcation variable and the choline metabolite score. CHD indicates
coronary heart disease; CI, conﬁdence interval; CVD, cardiovascular disease; and HR,
hazard ratio.
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concentrations were associated with a favorable car-
diometabolic risk factor proﬁle (lower low-density lipoprotein
cholesterol and triglycerides) and lower odds of diabetes
mellitus. In the same study, higher plasma phosphatidyl-
choline was associated with characteristics of both favorable
(higher high-density lipoprotein cholesterol and lower body
mass index) and unfavorable (higher low-density lipoprotein
cholesterol and triglycerides) cardiometabolic risk. These
ﬁndings suggest divergent roles of choline metabolites in the
pathogenesis of cardiometabolic risk factors and cerebrovas-
cular disease.31 Similarly, in our study, we have observed that
baseline choline concentrations are marginally associated
with the prevalence of being overweight and obesity (odds
ratios [95% CIs] per 1-SD increase, 1.13 [1.00–1.29] and 1.15
[1.00–1.34], respectively). Signiﬁcant positive correlations,
although they were weak, were observed for choline and
triglycerides (Spearman correlation coefﬁcient=0.08; P=0.04).
We have also observed cross-sectional inverse associations
between plasma betaine and prevalence of diabetes mellitus
and being overweight (odds ratios [95% CIs] per 1-SD
increase, 0.64 [0.55–0.74] and 0.88 [0.76–1.06], respec-
tively). Plasma betaine was inversely correlated with plasma
glucose and body mass index (Spearman correlation coefﬁ-
cient=0.18 and 0.07 [P<0.01 and P=0.01], respectively).
Altogether, these ﬁndings suggested a relationship between
these metabolites and cardiovascular risk factors.
The associations between dietary choline and betaine on
the risk of CVD have been evaluated in several prospective
studies.32–34 Compared with the lowest quartile of intake,
incident coronary heart disease after 14 years of follow-up in
participants from the ARIC (Atherosclerosis Risk in Commu-
nities) study was nonsigniﬁcantly higher in the highest
quartile of choline and choline plus betaine (HRs [95% CIs],
1.22 [0.91–1.64] and 1.14 [0.85–1.53], respectively), com-
pared with the lowest quartile.32 In women from the Jackson
Heart Study, greater choline intake was associated with lower
left ventricular mass (P=0.0006 for trend across choline
quartiles) and with abdominal aortic calcium score.34 Simi-
larly, higher dietary intakes of betaine and choline were not
associated with CVD risk in postmenopausal Dutch women
followed up for 97 months.33 On the other hand, ﬁndings
from the Nurses’ Health Study and Health Professionals
Follow-Up Study, including 80 978 women and 39 434 men,
respectively, followed up to 32 years, suggested that
higher phosphatidylcholine intake was associated with an
increased risk of CVD mortality after adjustment for potential
confounders.35
Previous published literature on this topic has mostly
focused on the formation of the gut microbiota–dependent
metabolite, TMAO.2,4,6 One of the most compelling studies
linking these metabolites with CVD complications was
reported by Wang and collaborators a few years ago.6 The
authors identiﬁed a novel pathway linking dietary phos-
phatidylcholine/choline, which can be converted by the
intestinal microbiota into trimethylamine and subsequently
converted into TMAO by hepatic ﬂavin-containing mono-
oxygenases, with CVD pathogenesis.13 These ﬁndings are
consistent with later in vivo and in vitro studies, suggesting
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0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
Q1(Ref.) Q2-Q4 Q1 Q2-Q4
A
dj
us
te
d 
H
R
 (9
5%
 C
I)
MedDiet group Control group
0.0
0.5
1.0
1.5
Q1(Ref.) Q2-Q4 Q1 Q2-Q4
A
dj
us
te
d 
H
R
 (9
5%
 C
I)
Control group MedDiet group
P for interaction: 0.05 P for interaction: 0.93
Figure. Multivariate adjusted hazard ratios (HRs; 95% conﬁdence intervals [CIs]) of incident cardiovascular disease for quartiles (Q) of choline
metabolite score (A) and betaine/choline ratio (B), stratiﬁed by intervention group (Mediterranean diet [MedDiet] interventions vs control group).
An inverse normal transformation was applied to raw baseline values and a weighted sum of concentrations of 5 metabolites in the choline
pathway (trimethylamine N-oxide, betaine, choline, phosphocholine, and a-glycerophosphocholine). The betaine/choline ratio was calculated by
dividing the raw values and then applying inverse normal transformations. Models adjusted for age, sex, body mass index, smoking, and family
history of premature heart disease. P values for interaction were derived from Cox models stratiﬁed by intervention group and adjusted as
above, including an interaction term between the intervention group and the continuous scores. Ref. indicates reference.
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that choline metabolites may increase the risk of atheroscle-
rosis and coronary heart disease.4,29,36,37 In addition, the
ability of oral broad-spectrum antibiotics to temporarily
suppress the production of TMAO suggests that intestinal
microorganisms may play an important role in the production
of TMAO from phosphatidylcholine in humans.4 Nevertheless,
our data did not support positive signiﬁcant associations
between plasma concentrations of TMAO and the risk of CVD
in individuals at high cardiovascular risk after 4.8 years of
follow-up. It is plausible that TMAO may be more relevant for
predicting recurrent CVD or CVD survival, being a marker of
established disease. Although TMAO was associated with
CVD mortality in participants undergoing incident dialysis in a
nested case-control study, when they replicated the ﬁndings
in an independent study, no differences were found in TMAO
concentrations between cases of cardiovascular death and
controls.7 One of the potential reasons for these associations
is that elevated TMAO levels are strongly related with renal
function in patients with chronic kidney disease, and they
normalize after renal transplantation.38 Therefore, because
kidney disease is a risk factor for CVD, TMAO was probably
associated with CVD mortality because individuals undergoing
dialysis have more risk of developing CVD.
Findings from a recent study, including 817 participants of
the CARDIA (Coronary Artery Risk Development in Young
Adults), followed up for 10 years, showed that TMAO was not
associated with coronary artery calcium incidence or other
measures of CVD risk, including insulin resistance, inﬂamma-
tory markers, and lipid proﬁle. The authors suggest that it is
possible that the adverse effect of TMAO may be more
relevant when concentrations of TMAO are higher than in their
sample or in later stages of the disease process.10 In another
study comparing the concentrations of TMAO, carnitine, and
choline in 34 obese individuals undergoing bariatric surgery,
TMAO was not elevated in obese patients before the surgery
but increased 2-fold after bariatric surgery.39 The authors
reported that these results were unexpected and suggested
that one explanation could be adaptive shifts in the gut
microbiota with increased ability to metabolize dietary choline
and carnitine to TMAO precursors.39 In contrast, carnitine and
choline, which are abundant in nutrients, such as in red meat
and eggs, and not microbiota dependent, were reduced after
lifestyle interventions and rebounded after bariatric surgery.39
Along these lines, choline and its metabolites can be
obtained from food sources or synthesized de novo. In a
randomized, controlled, crossover trial, it was observed that
dimethylamine and TMAO were signiﬁcantly higher after
consuming a diet high in ﬁsh.40 The authors reported that
plasma and urinary concentrations of TMAO were associated
with recent ﬁsh intake; therefore, high urinary TMAO
concentrations can be associated with healthy diets that are
rich in ﬁsh.40 Our data also showed that plasma TMAO is
correlated with the intake of ﬁsh and total meat (Spearman
correlation coefﬁcients, 0.12 and 0.08, respectively; P<0.01).
However, gut bacteria can synthesize TMAO from choline and,
hence, high urinary and plasma TMAO concentrations can also
originate from red meat consumption, which is generally
associated with adverse health outcomes. Thus, the global
pattern of metabolites, which reﬂects the totality of the diet,
might be more important in indicating dietary patterns than
are individual biomarkers.40 Findings from Tang et al suggest
that excessive consumption of phosphatidylcholine and
choline should be avoided by consuming a vegetarian or
high-ﬁber diet,4 which has similar characteristics as the
MedDiet intervention in the PREDIMED Study. It is established
that foods such as meat, egg yolks, and high-fat dairy
products, which are high in phosphatidylcholine, choline,
carnitine, and TMA, can serve as precursors of TMAO
production.6
Another point that has not been raised before and
deserves consideration is the possible attenuation of detri-
mental effects of metabolite proﬁles on CVD risk by adhering
to a MedDiet. Multiple lines of evidence could account for the
observed beneﬁts of the MedDiet on CVD, including the
reduction of low-grade inﬂammation,41 enhanced endothelial
function,42 lower oxidative stress,43 and lower levels of
oxidized low-density lipoprotein.44 Integrating diet information
with metabolomics data holds great potential for further
understanding biomarkers and mechanisms that relate diet,
health, and disease. The present work may have important
public health implications for focusing on dietary interven-
tions, such as adhering to the MedDiet and reducing the
intake of animal products, to improve metabolite proﬁles and,
consequently, the risk of CVD.
Several limitations and strengths of the present study
warrant mentioning. First, because the participants were
elderly Mediterranean individuals at high cardiovascular risk,
the results may not be extrapolated to other populations.
Notwithstanding, because of their increased risk of CVD, they
are an important therapeutic target. In addition, the case-
cohort design maximized the efﬁciency of the high-through-
put metabolomics proﬁling, which allowed us to extend the
results to all PREDIMED participants. Second, although we
adjusted for several potential confounders, residual con-
founding by other unknown or unmeasured variables cannot
be ruled out. Third, liquid chromatography–tandem mass
spectrometry–based metabolite measurements may not have
a direct clinical translation for each metabolite trait. Finally,
in the present analysis, we have only included choline
pathway metabolites, as subrogates of diet and gut micro-
biota–related metabolites, that have been identiﬁed in our
samples with the use of the metabolomics platform from the
present project. However, in the coming years, new metabo-
lites will probably need to be included in this group. The
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strengths of the present work include the prospective design,
the ability to control for potential confounders because of the
well-characterized comprehensive data of the randomized
PREDIMED trial, and the accurate and blind assessment of
incident CVD cases.
Conclusion
In conclusion, our ﬁndings demonstrated, for the ﬁrst time,
that metabolites from the choline pathway were associated
with an increased risk of major adverse cardiovascular events,
independent of traditional risk factors, in a Mediterranean
population at high cardiovascular risk.
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SUPPLEMENTAL MATERIAL 
 
Abbreviations: CVD, cardiovascular disease; TMAO, Trimethylamine-N-oxide; T2D, type 2 diabetes mellitus.  
  
Table S1. Characteristics of the choline pathway metabolites 
Metabolite HMDB ID Metabolic 
pathways 
Superclass/class/Subclass Origin Disease Biofluid 
Trimethylamine-N-
oxide (TMAO) 
HMDB00925 Betaine 
metabolism 
Organonitrogen 
compounds/Amines/Amine 
oxides and derivatives 
Drug metabolite 
Endogenous 
Microbial 
Kidney disease 
CVD 
Obesity 
T2D 
Blood 
Feces 
Saliva 
Urine 
Betaine HMDB00043 Betaine 
metabolism 
Glycine and 
serine 
metabolism 
Methionine 
metabolism 
Organic acids and 
derivatives/Carboxylic acids 
and derivatives/Amino acids 
Endogenous 
Diet 
Kidney disease 
Lung cancer  
CVD 
T2D  
Blood 
Breast Milk 
Saliva 
Urine 
Choline HMDB00097 Betaine 
metabolism 
Methionine 
metabolism 
Phospholipid 
biosynthesis 
Organonitrogen 
compounds/quaternary 
ammonium salts/cholines 
Drug 
Food 
Plant 
Lung cancer 
Alzheimer 
CVD 
Pre-diabetes  
Blood  
Breast Milk 
Cerebrospinal Fluid  
Feces 
Saliva 
Urine 
Phosphocholine HMDB00284 Phospholipid 
biosynthesis 
Sphingolipid 
metabolism 
Organonitrogen 
compound/quaternary 
ammonium salts/cholines 
Endogenous Alzheimer 
CVD 
Blood  
Breast Milk 
Cerebrospinal Fluid  
Saliva 
Urine 
Alphaglycerophosp
hocholine 
HMDB00086 Glycerophosphol
ipid metabolism 
Lipids/Glycerophospholipids/
glycerophosphocholine 
Endogenous 
Food 
Alzheimer 
CVD 
Blood 
Breast Milk 
Cerebrospinal Fluid  
Saliva 
  
Table S2. Means and SD of baseline plasma concentration of metabolites (micromole per liter) in the total population  
 Total population Cases (229) Non-cases (751) P value 
Trimethylamine-N-oxide 5.88 (6.48) 5.84 (6.28) 5.89 (6.55) 0.92 
Betaine 61.00 (17.60) 61.17 (16.66) 60.95 (17.90) 0.86 
Choline 23.75 (5.09) 25.04 (5.10) 23.36 (5.03) <0.001 
Phosphocholine 0.68 (0.66) 0.75 (0.81) 0.65 (0.61) 0.09 
Alphaglycerophosphocholine 3.47 (2.64) 3.98 (3.15) 3.31 (2.44) 0.57 
Cases: composite of cardiovascular disease events: myocardial infarction, stroke and cardiovascular death. 
 
 
 
Table S3. Means and SD of plasma concentration of metabolites (micromole per liter) per intervention group at baseline and 
one year of intervention 
 Control (303) Mediterranean Diet + 
extra-virgin olive oil (363) 
Mediterranean Diet + 
Nuts (314) 
BASELINE 
Trimethylamine-N-oxide 6.21 (7.22) 5.61 (5.99) 5.86 (6.28) 
Betaine 60.70 (16.12) 60.44 (18.11) 61.95 (18.40) 
Choline 23.14 (4.72) 23.99 (5.01) 24.07 (5.49) 
Phosphocholine 0.59 (0.54) 0.72 (0.68) 0.71 (0.74) 
Alphaglycerophosphocholine 3.31 (2.21) 3.44 (2.19) 3.65 (3.38) 
1-YEAR  
Trimethylamine-N-oxide 6.55 (7.75) 7.14 (9.73) 5.80 (7.10) 
Betaine 60.62 (15.92) 60.70 (18.21) 62.35 (18.35) 
Choline 24.08 (5.11) 24.42 (5.96) 24.46 (5.14) 
Phosphocholine 0.61 (0.55) 0.62 (0.53) 0.65 (0.50) 
Alphaglycerophosphocholine 3.86 (3.91) 3.50 (2.73) 4.26 (5.67) 
  
Table S4. Joint associations of the scores and intervention group with risk of cardiovascular disease and 
stroke 
  MedDiet interventions Control P interaction 
CARDIOVASCULAR DISEASE 
Choline metabolite score 
Q1 Ref. 1.74 (0.77, 3.89) 0.09 
Q2-Q4 1.70 (0.99, 2.91) 2.53 (1.41, 4.53)  
Betaine to choline ratio 
Q1 0.67 (0.45, 0.99) Ref.  0.91 
Q2-Q4 0.43 (0.25, 0.77) 0.74 (0.38,1.44)  
STROKE 
Choline metabolite score 
Q1 Ref. 2.48 (0.94, 6.53) 0.06 
Q2-Q4 1.76 (0.85, 3.63) 2.66 (1.22, 5.80)  
Betaine to choline ratio 
Q1 0.60 (0.37, 0.96) Ref. 0.76 
Q2-Q4 0.48 (0.23, 0.99) 0.77 (0.32, 1.84)  
 
An inverse normal transformation was applied to raw baseline values. To build the score, we applied a weighted sum of 
concentrations of five metabolites in the choline pathway (trimethylamine-N-oxide (TMAO), betaine, choline, 
phosphocholine and alphaglycerophosphocholine). The ratio between betaine and choline was calculated by dividing the raw 
values and then applying inverse normal transformations. Models were adjusted for age, sex, body mass index, family history 
of premature heart disease, smoking, physical activity (metabolic equivalent task units in min/d), hypertension, dyslipidemia, 
and diabetes. Abbreviations: TMAO, trimethylamine N oxide. P for interaction were derived from Cox models adjusted as 
above, including an interaction term between the intervention group (MedDiet vs. control) and the score as a continuous 
variable. MedDiet, Mediterranean diet. 
 
 
 
  
Table S5. Risk of cardiovascular disease and stroke by 1-year changes in choline pathway metabolites in the PREDIMED Study 
 Quartiles of metabolite concentration  
P trend 
HR per 1 
P value  Q1 Q2 Q3 Q4 SD increment 
CARDIOVASCULAR DISEASE 
TMAO        
Cases 39 35 47 55    
Multivariable Model 1 Ref. 0.98 (0.44, 2.14) 1.34 (0.64, 2.81) 1.39 (0.71, 2.74) 0.13 1.06 (0.88, 1.27) 0.54 
Multivariable Model 2 Ref. 1.08 (0.47, 2.50) 1.44 (0.65, 3.18) 1.42 (0.69, 2.92) 0.18 1.04 (0.85, 1.25) 0.72 
Betaine        
Cases 56 38 44 38    
Multivariable Model 1 Ref. 0.61 (0.36, 1.02) 0.59 (0.35, 0.99) 0.60 (0.35, 1.02) 0.08 0.80 (0.66, 0.98) 0.03 
Multivariable Model 2 Ref. 0.58 (0.34, 0.98) 0.63 (0.37, 1.06) 0.61 (0.35, 1.04) 0.11 0.83 (0.68, 1.01) 0.07 
Choline        
Cases 59 40 42 35    
Multivariable Model 1 Ref. 0.72 (0.43, 1.21) 0.81 (0.47, 1.39) 0.65 (0.36, 1.16) 0.20 0.89 (0.73, 1.09) 0.27 
Multivariable Model 2 Ref. 0.71 (0.41, 1.20) 0.81 (0.46, 1.42) 0.68 (0.38, 1.23) 0.28 0.92 (0.75, 1.14) 0.46 
Phosphocholine        
Cases 42 49 36 49    
Multivariable Model 1 Ref. 0.97 (0.58, 1.62) 0.94 (0.55, 1.63) 1.20 (0.71, 2.00) 0.47 1.15 (0.94, 1.41) 0.15 
Multivariable Model 2 Ref. 0.95 (0.57, 1.60) 1.02 (0.58, 1.79) 1.21 (0.70, 2.06) 0.44 1.15 (0.93, 1.42) 0.18 
Alphaglycerophosphocholine        
Cases 47 52 29 47    
Multivariable Model 1 Ref. 1.12 (0.63, 1.99) 0.77 (0.41, 1.44) 1.02 (0.58, 1.81) 0.79 1.10 (0.91, 1.33) 0.30 
Multivariable Model 2 Ref. 1.07 (0.59, 1.92) 0.78 (0.41, 1.49) 1.05 (0.59, 1.88) 0.92 1.14 (0.94, 1.38) 0.17 
STROKE 
TMAO        
Cases 21 20 24 30    
Multivariable Model 1 Ref. 1.04 (0.35, 3.03) 1.24 (0.44, 3.54) 1.29 (0.51, 3.26) 0.42 1.02 (0.80, 1.28) 0.90 
Multivariable Model 2 Ref. 1.16 (0.36, 3.65) 1.35 (0.45, 4.09) 1.34 (0.50, 3.59) 0.47 0.99 (0.78, 1.26) 0.82 
Betaine        
Cases 31 17 25 22    
Multivariable Model 1 Ref. 0.47 (0.23, 0.96) 0.60 (0.31, 1.14) 0.63 (0.32, 1.23) 0.29 0.84 (0.64, 1.09) 0.20 
Multivariable Model 2 Ref. 0.47 (0.23, 0.98) 0.64 (0.33, 1.23) 0.67 (0.34, 1.32) 0.40 0.86 (0.66, 1.13) 0.30 
Choline        
Cases 34 22 21 18    
Multivariable Model 1 Ref. 0.62 (0.32, 1.20) 0.61 (0.31, 1.21) 0.53 (0.25, 1.09) 0.10 0.89 (0.69, 1.16) 0.40 
Multivariable Model 2 Ref. 0.62 (0.32, 1.21) 0.64 (0.32, 1.29) 0.58 (0.28, 1.21) 0.18 0.93 (0.71, 1.22) 0.61 
Phosphocholine        
Cases 28 24 21 22    
Multivariable Model 1 Ref. 0.92 (0.49, 1.74) 1.08 (0.54, 2.15) 0.99 (0.50, 1.95) 0.93 1.00 (0.77, 1.30) 0.86 
Multivariable Model 2 Ref. 0.90 (0.47, 1.70) 1.17 (0.58, 2.39) 1.00 (0.49, 2.00) 0.89 0.98 (0.74, 1.30) 0.92 
Alphaglycerophosphocholine        
Cases 25 28 19 23    
Multivariable Model 1 Ref. 1.03 (0.56, 1.87) 0.84 (0.42, 1.68) 0.88 (0.46, 1.68) 0.57 1.04 (0.81, 1.34) 0.74 
Multivariable Model 2 Ref. 1.00 (0.53, 1.88) 0.88 (0.48, 1.77) 0.90 (0.45, 1.77) 0.69 1.08 (0.83, 1.39) 0.56 
Inverse normal transformation was applied to raw values of changes in metabolite concentration. Model 1 was adjusted for age, sex, BMI, family history of premature heart 
disease, and smoking and was stratified by intervention group. Model 2 was further adjusted for physical activity, hypertension, dyslipidemia, and diabetes. All models 
were adjusted for baseline metabolites levels and the interaction between baseline levels and 1-year changes. 
Figure S1. Flow chart of study participants 
 
  
7447 participants in 
PREDIMED 
794 
(10% random subcohort* with 
available plasma samples) 
288 total CVD cases 
229 total CVD cases 
with available 
plasma samples 
Baseline: 980  
n=751 non-cases 
n=229 CVD cases 
1-year: 923  
n=747 non-cases 
n=176 CVD cases 
788 
n=751 non-cases  
n= 37 internal cases† (they 
were included in the 229 total 
CVD cases, see the right box) 
*subcohort: a random, non-stratified sample of approximately 10% of PREDIMED participants at baseline. 
†internal cases: incident cases which were subcohort members (37 overlapping cases). They were treated as 
cases in the analysis (included in the 229) 
Exclusions 
n=3 had missing metabolite values 
at baseline 
n=3 had metabolite outliers 
identified by quality control  
Figure S2. Diagram of choline pathway 
 
  
Choline metabolism
Phosphatydylcholine
TMAO
TMA
Choline
Phosphoholine
CDP-choline
Betaine
DMA FMO3
*
CHCD
Choline kinase
Cytidylyl transferase
Choline phosphotransferase
Glycerophosphocholine
The figure shows key metabolic choline pathway. *Bacterial degration of choline by the gut microbiota. FMO3 indicates, Flavin-containing monoxygenase; CHCD, choline dehydrogenase; 
Figure S3. Correlation matrix for plasma metabolite levels 
Spearman Correlations coefficients of metabolites in the PREDIMED Study 
 
TMAO 1             
Betaine 0.16 1           
Choline 0.19 0.49 1         
Phosphocholine -0.01 0.16 0.15 1       
Alphaglycerophosphocholine -0.07 0.03 0.21 0.36 1     
Ratio betaine/choline 0.01 0.66 -0.26 0.06 -0.13 1   
Choline metabolite score 0.06 0.23 0.68 0.5 0.79 -0.31 1 
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